In 2018, an MoU was signed between the Ministry of Health of the Republic of Indonesia and the Ministry of Health of the Kingdom of the Netherlands. It included a collaboration on infectious diseases – the aim to, together, combat the rise of TB. This became the ground on which Delft Imaging joined the country’s effort against TB.
In 2020, Delft Imaging signed a Letter of Intent with the Ministry of Health of the Republic of Indonesia using the Computer-Aided Detection for Tuberculosis (CAD4TB) software. CAD4TB uses artificial intelligence to automatically detect TB-related abnormalities on a chest X-ray. The CAD4TBbox hosts the CAD4TB software, allowing offline use with the data stored locally instead of being dependent on internet availability. CAD4TB is endorsed by the World Health Organization (meets the Target Product Profile of the WHO of 90% sensitivity and 70% specificity), has been scientifically validated in over 65 publications and has been implemented in over 50 countries around the world, impacting the lives of over 14 million people to date.
In 2020, Delft Imaging registered the CAD4TB software with the Ministry of Health of the Republic of Indonesia to support the further roll-out of this TB screening solution. In that same year, in collaboration with Fullerton Health, e-Tirta medical centres and the Ministry of Health, CAD4TB was installed in several prisons and a factory in Jakarta. If any symptoms were found among the prisoners screened, the chest X-ray was taken to a mobile van equipped with CAD4TB. This initial pilot, screening approximately 1000 people, paved the way to the further utilization of CAD4TB in Indonesia. The pilot showed that the software helped to find more cases, reduced time and cost of TB diagnosis, and could be particularly helpful in hard-to-reach areas where it could help to optimize TB-detection results in support of the radiologists. During the project, users referred to CAD4TB as the ‘super assistant’ to radiologists in Indonesia in their efforts to eliminate TB.
In 2021, Delft Imaging supported a COVID-19 screening project funded by the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ), utilization CAD4COVID, a software solution built upon the existing technical infrastructure of CAD4TB, yet optimized for the detection of COVID-19 related abnormalities.
Later in 2021, Delft Imaging signed three Memorandums of Understanding (MoU) as part of a collaboration with the Faculty of Medicine of Universitas Indonesia to research the use of AI with the nation. The MoU’s were on CAD4TB, CAD4COVID and RetCAD (utilizing artificial intelligence on fundus imaging for the detection of Diabetic Retinopathy, Age-Related Macular Degeneration and Glaucoma).
In its efforts to further support its projects in Indonesia, Delft Imaging started a local office in Indonesia (Delft Imaging Indonesia) at the end of 2021, hosting IT specialists and local personnel to aid in installation, training and service support.
In early 2022, in collaboration with e-Tirta medical centres and the Ministry of Health, the TB efforts were scaled up. In the first quarter of the year, over 80,000 prisoners were screened. Later that year, the efforts were scaled up further in collaboration with the partners. CAD4TB was set up in 16 mobile clinics, covering 25 public health centres and supported the screening of an additional 110,000 people.
In the same year, Delft Imaging started a collaboration with International SOS, a global health and security service firm that provides healthcare services to mining companies and their employees across Indonesia. CAD4TB was set up in a mobile van and used to screen 10,000 employees in the mining industry for TB. Early 2023, another 15,000 employee were screened.
In 2023, Delft Imaging extended its collaboration with e-Tirta Medical Centres and the Ministry of Health of Indonesia to screen an additional 206,000 prisoners across 374 prisons in 33 provinces using CAD4TB.
The above figure shows H.E. Budi Gunadi Sadikin, Minister of Health of Indonesia, discussing the utilization of CAD4TB with partners during a World TB Event at Universitas Indonesia.
Making a difference
As a long-time partner to Indonesia’s TB screening efforts, researchers studied the use of CAD4TB among Indonesians living with Diabetes Mellitus (PLWD). This was particularly important as Diabetes Mellitus is a significant risk factor for TB. The study, already published in 2018, showed the potential use of CAD4TB as a triage tool for TB screening in PLWD, significantly reducing the need for microbiological examination.